Nobbledrug Healthcare Services Ltd (Noddledrug) won the public tender for D-EECT equipment (IQwave) in Kenya. This means that ChemoTech gets additionally an order from Nobbledrug of 25,000 EURO.
ChemoTech now has the important base necessary to succeed in a good market establishment in Kenya and other countries in the region. Gaining acceptance from the local academic profession is crucial in the launch of new medical technology and it take normally several years.
"It feels very satisfying that we have managed to establish such great interest in IQwave™ and D-EECT treatment in Kenya. Winning our first public tender is naturally very gratifying and will open doors for more success in the public as well as the private healthcare sectors in Africa", says CEO Mohan Frick.
Delivery and training in Kenya is expected to start by the end of the second quarter this year.
For more information, please contact:
Mohan Frick, CEO
Tel: +46 (0)10-218 93 00
Certified Adviser: Västra Hamnen Corporate Finance AB, Tel: +46 40 200 250,
This information is such information which Scandinavian ChemoTech AB (publ) are obligated to make public according to EU’s market abuse regulation and the law of securities market. The information was submitted by the agency of above stated contact person, to be made public on Friday March 15th 2019 at 15.10 (CET).
Scandinavian ChemoTech AB (publ)
ChemoTech is a life science company that possesses great medical expertise and technical knowledge. Our latest Product IQwave™ is an innovation within electroporation, specifically design for Electrochemotherapy for the treatment of different types of tumors. ChemoTech strives to contribute to a more accessible cancer care. ChemoTech’s shares (CMOTEC B) are listed on Nasdaq First North in Stockholm and Västra Hamnen Corporate Finance AB is the company’s Certified Adviser.
Se fullständiga pressmeddelande och andra nyheter från detta bolag hos Cision News